SCHEMBL3409959

SCHEMBL3409959

COc1cncc(-c2cnc(N3CCOCC3)cc2Nc2c(C)c(-c3cc(F)cc(F)c3)nc3ncccc23)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 7/20 0.45
ATR Q13535 2/20 0.42
ATRIP Q8WXE1 2/20 0.42
ROS1 P08922 2/20 0.38
FYN P06241 1/20 0.38
CLK1 P49759 1/20 0.37
DYRK1A Q13627 1/20 0.37
USP2 O75604 2/20 0.36
CASP1 P29466 2/20 0.36
CASP7 P55210 2/20 0.36
HIF1A Q16665 2/20 0.36
ALDH1A1 P00352 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
LRRK2 Q5S007 1/20 0.36
ABL1 P00519 1/20 0.36
NTRK1 P04629 1/20 0.36
YES1 P07947 1/20 0.36
PIM1 P11309 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL248111 0.81 PIK3CD (0.47) PIK3CAATRATRIPPIK3CD
SCHEMBL249060 0.79 PIK3CD (0.60) PIK3CAATRATRIPABL1NTRK1
SCHEMBL248832 0.78 ATR (0.42) PIK3CAATRATRIPROS1FYN
SCHEMBL245595 0.78 PIK3CD (0.41) PIK3CAATRATRIPROS1FYN
SCHEMBL247262 0.77 PIK3CD (0.50) PIK3CAATRATRIPROS1FYN
SCHEMBL253880 0.77 PIK3CA (0.51) PIK3CAMAPK1PIK3CD
SCHEMBL247470 0.76 PIK3CA (0.46) PIK3CAATRATRIPROS1FYN
SCHEMBL245564 0.76 PIK3CD (0.42) PIK3CAATRATRIPFYNCLK1
SCHEMBL245470 0.76 PIK3CD (0.47) PIK3CAATRATRIPFYNDYRK1A
SCHEMBL248473 0.75 PIK3CD (0.44) PIK3CAATRATRIPROS1FYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130090323-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2013-04-11 US disclosed
US-20130090323-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2013-04-11 US disclosed
US-20130090323-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2013-04-11 US disclosed
WO-2012003283-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY AMGEN INC. (US) 2012-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130090323-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, MALT1, BCL9 PIK3CA 28/4885ATR 203/4885ATRIP 1571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.